Erlotinib clinical trials
Also written Tarceva, OSI-774 and CP-358,774.
How each study uses erlotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the erlotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Nov 2004 · TARCEVA · NDA 021743 (FDA, Drugs@FDA)
- European Union
- 19 Sept 2005 · Tarceva · EMEA/H/C/000618 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Brand
- Tarceva
- 228
Studies by the year they started
503 studies that test it; most in 2006 (67); 2 more planned to start later
| Year | Studies |
|---|---|
| 2001 | 10 |
| 2002 | 27 |
| 2003 | 21 |
| 2004 | 30 |
| 2005 | 41 |
| 2006 | 67 |
| 2007 | 61 |
| 2008 | 49 |
| 2009 | 49 |
| 2010 | 23 |
| 2011 | 31 |
| 2012 | 21 |
| 2013 | 18 |
| 2014 | 17 |
| 2015 | 12 |
| 2016 | 8 |
| 2017 | 7 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 77 · Other 430
National Cancer Institute (NCI) (63) · Hoffmann-La Roche (36) · M.D. Anderson Cancer Center (35) · OSI Pharmaceuticals (12) · SCRI Development Innovations, LLC (10) · Genentech, Inc. (9) · Memorial Sloan Kettering Cancer Center (9) · Dana-Farber Cancer Institute (8)
Often tested with
Tested in the same studies.
Bevacizumab (64) · Gemcitabine (36) · Docetaxel (18) · Capecitabine (17) · Pemetrexed (15) · Cisplatin (14) · Sorafenib (13) · Carboplatin (12)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Erlotinib is the comparator. A study of two new drugs counts under both.
- 1Abemaciclib · Eli Lilly and Company
Reaching primary completion within a year · 3
Studies that test erlotinib.
- Dec 2026Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)Phase 2 · Canadian Cancer Trials Group
- Aug 2027Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelPhase 1/2 · UNC Lineberger Comprehensive Cancer Center
- Sep 2027The Drug Rediscovery Protocol (DRUP Trial)Phase 2 · The Netherlands Cancer Institute
Studies
Open first, then newest update. How each study uses erlotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 507
- A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal CancerNot yet recruitingPhase 2Korea University Anam HospitalNCT07941310Written as erlotinibHow we know
- Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Head and Neck Cancer in a Rural Midwest United States PopulationRecruitingPhase 2Mayo ClinicNCT06997068Written as Erlotinib HydrochlorideHow we know
- Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerRecruitingPhase 2National Cancer Institute (NCI)NCT04981509Written as ErlotinibHow we know
- Epidermal Growth Factor Receptor Inhibition for KeratinopathiesNot yet recruitingPhase 1/2Northwestern UniversityNCT06545695Written as ErlotinibHow we know
- Erlotinib for Hepatocellular Carcinoma ChemopreventionNot yet recruitingPhase 2University of Texas Southwestern Medical CenterNCT04172779Written as erlotinib hydrochlorideHow we know
- Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelRecruitingPhase 1/2UNC Lineberger Comprehensive Cancer CenterNCT06483555Written as ErlotinibHow we know
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingPhase 2Canadian Cancer Trials GroupNCT03297606Written as ErlotinibHow we know
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingPhase 2Ulrik LassenNCT04341181Written as ErlotinibHow we know
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingPhase 1/2China Medical University HospitalNCT06071013Written as Nintedanib, gefitinib, erlotinib, afatinib, osimertinibHow we know
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingPhase 2The Netherlands Cancer InstituteNCT02925234Written as ErlotinibHow we know
- A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered CancerRecruitingPhase 2Asan Medical CenterNCT05904457Written as erlotinibHow we know
- Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid TumorsActive, not recruitingPhase 1National Cancer Institute (NCI)NCT00045201Written as Erlotinib HydrochlorideHow we know
- Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01660971Written as Erlotinib HydrochlorideHow we know
- Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT01708954Written as Erlotinib HydrochlorideHow we know
- A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Active, not recruitingPhase 3Eli Lilly and CompanyNCT02411448Written as ErlotinibHow we know
- Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid CarcinomaCompletedNot applicableInstitut Claudius RegaudNCT00144976Written as TarcevaHow we know
- Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung CancerCompletedPhase 2University Hospital, LimogesNCT01350817Written as Erlotinib + docetaxelHow we know
- Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.CompletedPhase 3ETOP IBCSG Partners FoundationNCT01652469Written as ErlotinibHow we know
- BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)CompletedPhase 2ETOP IBCSG Partners FoundationNCT01562028Written as ErlotinibHow we know
- OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT00076310Written as OSI-774How we know
See all 507 studies that test erlotinib →
Given beside what is tested · 164 — erlotinib is usual care or a partner of the new treatment
- To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerRecruitingPhase 2OBI Pharma, IncNCT05442060Written as Erlotinib (150 mg daily)How we know
- GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT00878163Written as Erlotinib HydrochlorideHow we know
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNot applicableNational Cancer Institute (NCI)NCT02194738Written as ErlotinibHow we know
- Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid TumorsCompletedPhase 1Alaunos TherapeuticsNCT00591383Written as erlotinibHow we know
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C MutationActive, not recruitingPhase 1Genentech, Inc.NCT04449874Written as ErlotinibHow we know
- Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene AmplificationsTerminatedPhase 1Boundless Bio, Inc.NCT05827614Written as ErlotinibHow we know
- Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell CarcinomaCompletedPhase 2M.D. Anderson Cancer CenterNCT00942734Written as ErlotinibHow we know
- Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic CancerTerminatedPhase 2M.D. Anderson Cancer CenterNCT00640978Written as ErlotinibHow we know
- Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingPhase 2NRG OncologyNCT03137771Written as Erlotinib HydrochlorideHow we know
- A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)CompletedPhase 1AstraZenecaNCT00600496Written as ErlotinibHow we know
- Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR MutationsCompletedPhase 3Guangdong Association of Clinical TrialsNCT02759614Written as ErlotinibHow we know
- A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor MutationsCompletedPhase 2Eli Lilly and CompanyNCT01897480Written as ErlotinibHow we know
- A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2ExelixisNCT00596648Written as erlotinibHow we know
- A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary SiteCompletedPhase 2Hoffmann-La RocheNCT03498521Written as ErlotinibHow we know
- Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based ChemotherapyCompletedPhase 2Astellas Pharma IncNCT01186861Written as erlotinibHow we know
- Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) GeneCompletedPhase 2Astellas Pharma IncNCT01221077Written as ErlotinibHow we know
- A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid TumorsActive, not recruitingPhase 1AbbVieNCT02099058Written as ErlotinibHow we know
- Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLCTerminatedPhase 1Io TherapeuticsNCT02991651Written as erlotinibHow we know
- Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic CancerCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT00954525Written as Gemcitabine and ErlotinibHow we know
- Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT02535338Written as Erlotinib HydrochlorideHow we know
Showing 20 of 164.
As the comparator · 15 — what is tested is compared with erlotinib
- Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLCNot yet recruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT04455594Written as ErlotinibHow we know
- A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung CancerActive, not recruitingPhase 3Eli Lilly and CompanyNCT02152631Written as ErlotinibHow we know
- First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) MetastasesCompletedPhase 2/3Alpha Biopharma (Jiangsu) Co., Ltd.NCT03653546Written as ErlotinibHow we know
- A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating MutationsTerminatedPhase 3Astellas Pharma Global Development, Inc.NCT02588261Written as ErlotinibHow we know
- A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerCompletedPhase 3AstraZenecaNCT02352948Written as ErlotinibHow we know
- KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line ChemotherapyTerminatedPhase 3Kadmon Corporation, LLCNCT01487174Written as ErlotinibHow we know
- Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based TreatmentCompletedPhase 2Spectrum Pharmaceuticals, IncNCT00606502Written as ErlotinibHow we know
- LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyCompletedPhase 3Boehringer IngelheimNCT01523587Written as erlotinibHow we know
- A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)CompletedPhase 2Merck Sharp & Dohme LLCNCT00654420Written as ErlotinibHow we know
- Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior ChemotherapyCompletedPhase 3Genzyme, a Sanofi CompanyNCT00364351Written as ErlotinibHow we know
- ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung CancerCompletedPhase 3PfizerNCT01360554Written as Active Comparator (erlotinib)How we know
- A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLCCompletedPhase 2Bristol-Myers SquibbNCT00743938Written as ErlotinibHow we know
- A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy RegimenCompletedPhase 2PfizerNCT00769067Written as ErlotinibHow we know
- SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)CompletedPhase 2Merck Sharp & Dohme LLCNCT00732810Written as ErlotinibHow we know
- Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung CancerCompletedPhase 2PfizerNCT00321815Written as PF-3512676 + ErlotinibHow we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Newly registered1
- A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal CancerNov 17, 2026NCT07941310
Codes
What other systems call erlotinib · ClinicalTrials.gg INT006571
- MeSH (NLM) D000069347Erlotinib HydrochlorideConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) J4T82NDH7EERLOTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 337525Confirmed FDA, Wikidata
- Wikidata Q418369erlotinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65530ErlotinibOne source FDA
- DrugBank DB00530One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069347 | Erlotinib Hydrochloride | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | J4T82NDH7E | ERLOTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 337525 | — | Confirmed FDA, Wikidata |
| Wikidata | Q418369 | erlotinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65530 | Erlotinib | One source FDA |
| DrugBank | DB00530 | — | One source Wikidata |
Also registered as erlotinib hydrochloride (UNII DA87705X9K · RxNorm 477320).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.